Feng Ren News Today

InSilico Medicine, a clinical-stage company utilizing generative artificial intelligence (AI) for drug discovery, reveals the development of

Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

After having natural human-like conversations with humans, AI could potentially be treating them medically, as the first drug fully generated by artificial intelligence has now entered clinical...

Washington DC (UPI) Jul 2, 2023 - The first dose of a drug developed by artificial intelligence has been delivered to its first patient.

In a first, a drug discovered and designed using artificial intelligence (AI) for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic disease that causes scarring in the lungs, has entered human clinical trials.Hong Kong-based ...

In a first, a drug discovered and designed using artificial intelligence (AI) for the treatment of idiopathic pulmonary fibrosis (IPF)

In a first, a drug discovered and designed using artificial intelligence (AI) for the treatment of idiopathic pulmonary fibrosis (IPF)

Insilico Medicine, a biotechnology company based in Hong Kong, announced that human patients have begun receiving the drug INS018_055, an anti-fibrotic small molecule inhibitor.

The first-ever drug generated by artificial intelligence has entered Phase 2 clinical trials, with the first dose successfully administered to a human, Insilico Medicine announced yesterday.

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 11, entitled, "Precious1GPT: multimodal transformer-based transfer learning for aging clock development and feature importance analysis for aging and age-related disease target discovery."